DASHES Protocol: Development and Feasibility Testing of a Tailored Community Programme to Support People in Recovery from Problematic Alcohol and Drug Use to Cut Down or Stop Smoking Using Co-Creation.
addiction
development
feasibility
harm reduction
intervention
smoking cessation
tobacco
trauma informed
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
21 10 2022
21 10 2022
Historique:
received:
13
09
2022
revised:
30
09
2022
accepted:
07
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Despite the continued global decline in adult tobacco prevalence, rates continue to be significantly higher in groups with problematic drug or alcohol use (PDA). It is estimated that people with alcohol, drug or mental health problems account for approximately half of all smoking deaths. In the UK, there are free stop smoking services for the general population. However, these services have been criticized as unsuitable for people in recovery from PDA due to their design, time-limited support, strict requirement for smoking abstinence and lack of consideration of harm reduction approaches. This has led to calls for alternative approaches to support this marginalized and underserved group. This research study seeks to respond to this call by co-creating and feasibility testing a tailored, trauma-informed service specifically for people seeking help for PDA, who are not in immediate crisis, and who may also want to reduce or stop their tobacco smoking. The mixed-method study design has two parts. The development study (part one) will use participatory peer research methods to work with the target client group and key stakeholders involved in service delivery, commissioning, and policy to design the service (intervention). The feasibility study (part two) will test the delivery of the intervention protocol and capture data that will enable the assessment of whether progression to a future pilot randomized control trial is merited. The outcome of this study will be a theoretically informed, co-created intervention with the potential to improve population health by supporting people with problematic drug or alcohol use to cut down or stop tobacco smoking.
Sections du résumé
BACKGROUND
Despite the continued global decline in adult tobacco prevalence, rates continue to be significantly higher in groups with problematic drug or alcohol use (PDA). It is estimated that people with alcohol, drug or mental health problems account for approximately half of all smoking deaths. In the UK, there are free stop smoking services for the general population. However, these services have been criticized as unsuitable for people in recovery from PDA due to their design, time-limited support, strict requirement for smoking abstinence and lack of consideration of harm reduction approaches. This has led to calls for alternative approaches to support this marginalized and underserved group. This research study seeks to respond to this call by co-creating and feasibility testing a tailored, trauma-informed service specifically for people seeking help for PDA, who are not in immediate crisis, and who may also want to reduce or stop their tobacco smoking.
METHODS
The mixed-method study design has two parts. The development study (part one) will use participatory peer research methods to work with the target client group and key stakeholders involved in service delivery, commissioning, and policy to design the service (intervention). The feasibility study (part two) will test the delivery of the intervention protocol and capture data that will enable the assessment of whether progression to a future pilot randomized control trial is merited.
CONCLUSIONS
The outcome of this study will be a theoretically informed, co-created intervention with the potential to improve population health by supporting people with problematic drug or alcohol use to cut down or stop tobacco smoking.
Identifiants
pubmed: 36294287
pii: ijerph192013709
doi: 10.3390/ijerph192013709
pmc: PMC9603715
pii:
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Chief Scientist Office
ID : HIPS /21/60
Pays : United Kingdom
Références
BMC Med. 2015 Sep 16;13:224
pubmed: 26377409
J Psychoactive Drugs. 2013 Nov-Dec;45(5):386-93
pubmed: 24592664
Int J Equity Health. 2020 Dec 4;19(1):215
pubmed: 33276793
Nicotine Tob Res. 2021 Feb 16;23(3):462-470
pubmed: 32770246
Drug Alcohol Rev. 2021 Sep;40(6):998-1002
pubmed: 33774886
Drug Alcohol Rev. 2013 Mar;32(2):133-40
pubmed: 22994631
Drug Alcohol Depend. 2017 Nov 1;180:178-192
pubmed: 28910690
JAMA. 1996 Apr 10;275(14):1097-103
pubmed: 8601929
J Clin Epidemiol. 2020 Jul;123:177-179
pubmed: 32229248
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
Cochrane Database Syst Rev. 2016 Nov 23;11:CD010274
pubmed: 27878808
BMC Med. 2020 Apr 10;18(1):78
pubmed: 32272927
Cochrane Database Syst Rev. 2016 Sep 14;9:CD010216
pubmed: 27622384
Addict Behav. 2019 Aug;95:35-40
pubmed: 30831339
Prev Med. 1994 Jan;23(1):61-9
pubmed: 8016035
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
BMJ. 2021 Sep 30;374:n2061
pubmed: 34593508
Addiction. 2021 Jul;116(7):1747-1756
pubmed: 33197093
Br J Addict. 1989 Jul;84(7):791-9
pubmed: 2758152
BMC Health Serv Res. 2014 Jul 14;14:304
pubmed: 25017205
Harm Reduct J. 2020 Jan 31;17(1):10
pubmed: 32005119